{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:18:59Z","timestamp":1791497939114,"version":"4.3.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:00:00Z","timestamp":1737331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:00:00Z","timestamp":1737331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"DOI":"10.1186\/s12883-024-04007-1","type":"journal-article","created":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T05:09:51Z","timestamp":1737349791000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Real-world satisfaction and experience with injection and autoinjector device for ofatumumab indicated for multiple sclerosis"],"prefix":"10.1186","volume":"25","author":[{"given":"Amy Perrin","family":"Ross","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Nicholas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Hui","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazneen Fatima","family":"Shaikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Cortright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Hawkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,20]]},"reference":[{"key":"4007_CR1","doi-asserted-by":"publisher","first-page":"e1029","DOI":"10.1212\/wnl.0000000000007035","volume":"92 10","author":"MT Wallin","year":"2019","unstructured":"Wallin MT, Culpepper WJ, Campbell JD, Nelson LM, Langer-Gould A, Marrie RA, et al. The prevalence of MS in the United States: a population-based estimate using health claims data. Neurology. 2019;92 10:e1029\u201340. https:\/\/doi.org\/10.1212\/wnl.0000000000007035.","journal-title":"Neurology"},{"issue":"2","key":"4007_CR2","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1056\/NEJMra1401483","volume":"378","author":"DS Reich","year":"2018","unstructured":"Reich DS, Lucchinetti CF, Calabresi PA. Multiple sclerosis. New Engl J Med. 2018;378 2:169\u201380. https:\/\/doi.org\/10.1056\/NEJMra1401483.","journal-title":"New Engl J Med."},{"key":"4007_CR3","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1016\/s0140-6736(18)30481-1","volume":"391 10130","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O. Multiple sclerosis. Lancet. 2018;391 10130:1622\u201336. https:\/\/doi.org\/10.1016\/s0140-6736(18)30481-1.","journal-title":"Lancet"},{"key":"4007_CR4","doi-asserted-by":"publisher","unstructured":"Faraclas E, Merlo A, Lynn J, Lau JD. Perceived facilitators, needs, and barriers to health related quality of life in people with multiple sclerosis: a qualitative investigation. J Patient Rep Outcomes. 2022;6 1:89. https:\/\/doi.org\/10.1186\/s41687-022-00496-1.","DOI":"10.1186\/s41687-022-00496-1"},{"key":"4007_CR5","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/s1474-4422(20)30067-3","volume":"19 4","author":"A He","year":"2020","unstructured":"He A, Merkel B, Brown JWL, Zhovits Ryerson L, Kister I, Malpas CB, et al. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol. 2020;19 4:307\u201316. https:\/\/doi.org\/10.1016\/s1474-4422(20)30067-3.","journal-title":"Lancet Neurol"},{"key":"4007_CR6","doi-asserted-by":"publisher","first-page":"175628642110195","DOI":"10.1177\/17562864211019574","volume":"14","author":"P Iaffaldano","year":"2021","unstructured":"Iaffaldano P, Lucisano G, Caputo F, Paolicelli D, Patti F, Zaffaroni M, et al. Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies. Ther Adv Neurol Disord. 2021;14:17562864211019574. https:\/\/doi.org\/10.1177\/17562864211019574.","journal-title":"Ther Adv Neurol Disord"},{"key":"4007_CR7","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s11940-021-00677-1","volume":"23 7","author":"A Simpson","year":"2021","unstructured":"Simpson A, Mowry EM, Newsome SD. Early aggressive treatment approaches for multiple sclerosis. Curr Treat Options Neurol. 2021;23 7:19. https:\/\/doi.org\/10.1007\/s11940-021-00677-1.","journal-title":"Curr Treat Options Neurol"},{"key":"4007_CR8","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1007\/s00415-021-10836-8","volume":"269 3","author":"M Filippi","year":"2022","unstructured":"Filippi M, Danesi R, Derfuss T, Duddy M, Gallo P, Gold R, et al. Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis. J Neurol. 2022;269 3:1670\u20137. https:\/\/doi.org\/10.1007\/s00415-021-10836-8.","journal-title":"J Neurol"},{"key":"4007_CR9","doi-asserted-by":"publisher","unstructured":"Yang JH, Rempe T, Whitmire N, Dunn-Pirio A, Graves JS. Therapeutic advances in multiple sclerosis. Front Neurol. 2022;13. https:\/\/doi.org\/10.3389\/fneur.2022.824926.","DOI":"10.3389\/fneur.2022.824926"},{"key":"4007_CR10","doi-asserted-by":"publisher","unstructured":"G\u00e4rtner J, Hauser SL, Bar-Or A, Montalban X, Cohen JA, Cross AH, et al. Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: results from ASCLEPIOS I and II. Mult Scler. 2022;28 10:1562\u201375. https:\/\/doi.org\/10.1177\/13524585221078825.","DOI":"10.1177\/13524585221078825"},{"key":"4007_CR11","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1056\/NEJMoa1917246","volume":"383 6","author":"SL Hauser","year":"2020","unstructured":"Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, et al. Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med. 2020;383 6:546\u201357. https:\/\/doi.org\/10.1056\/NEJMoa1917246.","journal-title":"N Engl J Med"},{"key":"4007_CR12","doi-asserted-by":"publisher","unstructured":"Rau D, Eichau S, Borriello G, Cerqueira J, Wagner C. Assessment of the treating physicians\u2019 first-hand experience with handling and satisfaction of ofatumumab therapy: findings from the PERITIA survey conducted in Europe. BMC Neurol. 2023;23 1:147. https:\/\/doi.org\/10.1186\/s12883-023-03190-x.","DOI":"10.1186\/s12883-023-03190-x"},{"key":"4007_CR13","first-page":"12","volume":"13","author":"MJ Williams","year":"2020","unstructured":"Williams MJ, Robinson J, Elliott-Maksymowicz KL, Deshpande B. Evaluating perceptions of ofatumumab in multiple sclerosis via social media listening\u2013early 3 months post approval data. Safety. 2020;13:12.","journal-title":"Safety"},{"key":"4007_CR14","unstructured":"United States Food Drug Administration. Kesimpta \u2013 prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/125326s070lbl.pdf (2020). Accessed 19-Jul 2023."},{"key":"4007_CR15","doi-asserted-by":"publisher","unstructured":"Hoffmann FA, Trenova A, Llaneza MA, Fischer J, Lus G, von Bredow D, et al. Patient satisfaction with ExtaviPro\u2122 30G, a new auto-injector for administering interferon \u03b2-1b in multiple sclerosis: results from a real-world, observational EXCHANGE study. BMC Neurol. 2017;17 1:156. https:\/\/doi.org\/10.1186\/s12883-017-0928-9.","DOI":"10.1186\/s12883-017-0928-9"},{"key":"4007_CR16","doi-asserted-by":"publisher","unstructured":"Ross AP, Besser C, Naval S, Stoneman D, Gaunt H, Barker N. Patient and nurse preference for Sensoready autoinjector pen versus other autoinjectors in multiple sclerosis: results from a pilot multicenter survey. BMC Neurol. 2023;23 1:85. https:\/\/doi.org\/10.1186\/s12883-023-03100-1.","DOI":"10.1186\/s12883-023-03100-1"},{"key":"4007_CR17","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2147\/por.S51838","volume":"4","author":"K Thakur","year":"2013","unstructured":"Thakur K, Manuel L, Tomlinson M. Autoinjectors for administration of interferon beta-1b in multiple sclerosis: patient preferences and the ExtaviPro\u2122 30G and betacomfort(\u00ae) devices. Pragmat Obs Res. 2013;4:19\u201326. https:\/\/doi.org\/10.2147\/por.S51838.","journal-title":"Pragmat Obs Res"},{"key":"4007_CR18","unstructured":"Bar-Or A, Fox E, Goodyear A, Ludwig I, Bagger M, H\u00e4ring DA, et al. Onset of B-cell depletion with subcutaneous administration of ofatumumab in relapsing multiple sclerosis: results from the APLIOS bioequivalence study. Mult Scler. 2020;26 1 suppl;90-159."},{"key":"4007_CR19","doi-asserted-by":"publisher","unstructured":"Farej R, Rametta M, La Rose A, Quillen A, McLeod K. A prospective, observational, multicenter study assessing adherence to interferon beta-1b therapy and patient satisfaction using the BETACONNECT auto-injector. Neurol Ther. 2022;11 1:373\u201384. https:\/\/doi.org\/10.1007\/s40120-022-00323-1.","DOI":"10.1007\/s40120-022-00323-1"},{"key":"4007_CR20","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s40744-018-0134-2","volume":"6 1","author":"A Saraux","year":"2019","unstructured":"Saraux A, Hudry C, Zinovieva E, Herman-Demars H. Use of auto-injector for methotrexate subcutaneous self-injections: high satisfaction level and good compliance in SELF-I study, a randomized, open-label, parallel group study. Rheumatol Ther. 2019;6 1:47\u201360. https:\/\/doi.org\/10.1007\/s40744-018-0134-2.","journal-title":"Rheumatol Ther"},{"issue":"4","key":"4007_CR21","doi-asserted-by":"publisher","first-page":"e0230959","DOI":"10.1371\/journal.pone.0230959","volume":"15","author":"S Sauri-Su\u00e1rez","year":"2020","unstructured":"Sauri-Su\u00e1rez S, Qui\u00f1ones-Aguilar S, Contreras-Mar\u00edn A, Ramiro-Guerrero EO, Z\u00fa\u00f1iga-Garc\u00eda D, Salinas-V\u00e1zquez L, et al. Adherence to self-administering interferon-\u03b21a using RebiSmart\u00ae device in Mexican patients with relapsing multiple sclerosis. PLoS One. 2020;15 4:e0230959. https:\/\/doi.org\/10.1371\/journal.pone.0230959.","journal-title":"PLoS ONE"},{"key":"4007_CR22","doi-asserted-by":"publisher","first-page":"259","DOI":"10.4155\/tde-2023-0022","volume":"14 4","author":"RD Terlizzi","year":"2023","unstructured":"Terlizzi RD, King M, Blohm C. Usability validation of the Sensoready\u00ae Pen in patients with relapsing multiple sclerosis. Therapeutic Delivery. 2023;14 4:259\u201368. https:\/\/doi.org\/10.4155\/tde-2023-0022.","journal-title":"Therapeutic Delivery"},{"key":"4007_CR23","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/s1474-4422(17)30470-2","volume":"17 2","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17 2:162\u201373. https:\/\/doi.org\/10.1016\/s1474-4422(17)30470-2.","journal-title":"Lancet Neurol"},{"key":"4007_CR24","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1212\/wnl.0000000000002469","volume":"86 11","author":"P Dilokthornsakul","year":"2016","unstructured":"Dilokthornsakul P, Valuck RJ, Nair KV, Corboy JR, Allen RR, Campbell JD. Multiple sclerosis prevalence in the United States commercially insured population. Neurology. 2016;86 11:1014\u201321. https:\/\/doi.org\/10.1212\/wnl.0000000000002469.","journal-title":"Neurology"},{"key":"4007_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2022-329049","author":"L Prosperini","year":"2022","unstructured":"Prosperini L, Lucchini M, Ruggieri S, Tortorella C, Haggiag S, Mirabella M, et al. Shift of multiple sclerosis onset towards older age. J Neurol Neurosurg Psychiatry. 2022. https:\/\/doi.org\/10.1136\/jnnp-2022-329049.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"4007_CR26","doi-asserted-by":"publisher","first-page":"e1818","DOI":"10.1212\/wnl.0000000000200151","volume":"98 18","author":"AM Langer-Gould","year":"2022","unstructured":"Langer-Gould AM, Gonzales EG, Smith JB, Li BH, Nelson LM. Racial and ethnic disparities in multiple sclerosis prevalence. Neurology. 2022;98 18:e1818\u201327. https:\/\/doi.org\/10.1212\/wnl.0000000000200151.","journal-title":"Neurology"},{"key":"4007_CR27","doi-asserted-by":"publisher","first-page":"104246","DOI":"10.1016\/j.msard.2022.104246","volume":"68","author":"S El Mahdaoui","year":"2022","unstructured":"El Mahdaoui S, Romme Christensen J, Magyari M, Wandall-Holm MF, Sellebjerg F. Intravenous ofatumumab treatment of multiple sclerosis and related disorders: an observational study. Mult Scler Relat Disord. 2022;68:104246. https:\/\/doi.org\/10.1016\/j.msard.2022.104246.","journal-title":"Mult Scler Relat Disord"},{"key":"4007_CR28","doi-asserted-by":"publisher","first-page":"102124","DOI":"10.1016\/j.msard.2020.102124","volume":"42","author":"F Patti","year":"2020","unstructured":"Patti F, Chisari C, D\u2019Amico E, Annovazzi P, Banfi P, Bergamaschi R, et al. Clinical and patient determinants of changing therapy in relapsing-remitting multiple sclerosis (SWITCH study). Mult Scler Relat Disord. 2020;42:102124. https:\/\/doi.org\/10.1016\/j.msard.2020.102124.","journal-title":"Mult Scler Relat Disord"},{"key":"4007_CR29","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1007\/s12325-020-01367-1","volume":"37 7","author":"J Bowen","year":"2020","unstructured":"Bowen J, Mehta R, Pelletier C, Tian M, Noxon V, Johnson BH, et al. Treatment patterns among patients with multiple sclerosis initiating second-line disease-modifying therapy. Adv Ther. 2020;37 7:3163\u201377. https:\/\/doi.org\/10.1007\/s12325-020-01367-1.","journal-title":"Adv Ther"},{"key":"4007_CR30","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.msard.2018.11.023","volume":"27","author":"E Cameron","year":"2019","unstructured":"Cameron E, Rog D, McDonnell G, Overell J, Pearson O, French DP. Factors influencing multiple sclerosis disease-modifying treatment prescribing decisions in the United Kingdom: a qualitative interview study. Mult Scler Relat Disord. 2019;27:378\u201382. https:\/\/doi.org\/10.1016\/j.msard.2018.11.023.","journal-title":"Mult Scler Relat Disord"},{"issue":"4","key":"4007_CR31","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s40271-023-00617-y","volume":"16","author":"S Tatlock","year":"2023","unstructured":"Tatlock S, Sully K, Batish A, Finbow C, Neill W, Lines C, et al. Individual differences in the patient experience of relapsing multiple sclerosis (RMS): a multi-country qualitative exploration of drivers of treatment preferences among people living with RMS. Patient. 2023;16 4:345\u201357. https:\/\/doi.org\/10.1007\/s40271-023-00617-y.","journal-title":"Patient"},{"key":"4007_CR32","doi-asserted-by":"publisher","unstructured":"Colten SS, di Cantogno EV, Jack D. Preferences and perspectives of specialist multiple sclerosis nurses and patients with multiple sclerosis regarding the New RebiSmart\u00ae 3.0 autoinjector versus other assistive devices. Med Devices (Auckl). 2024;17:59\u201371. https:\/\/doi.org\/10.2147\/MDER.S438883.","DOI":"10.2147\/MDER.S438883"},{"key":"4007_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.105888","volume-title":"Baseline characteristics and 6-month tolerability, safety and persistence in a real-world cohort of multiple sclerosis patients initiating ofatumumab","author":"M Amin","year":"2023","unstructured":"Hersh CM, Gorritz M, Chen CC, Tuly R, Gu Y, Gadkari A, et al. Real-world persistence and adherence of ofatumumab versus oral and injectable disease-modifying therapies in patients with multiple sclerosis. Mult Scler Relat Disord. 2024;91:105888. https:\/\/doi.org\/10.1016\/j.msard.2024.105888."}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-024-04007-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-024-04007-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-024-04007-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T17:06:54Z","timestamp":1737392814000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-024-04007-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,20]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4007"],"URL":"https:\/\/doi.org\/10.1186\/s12883-024-04007-1","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,20]]},"assertion":[{"value":"23 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approval for this study was waived by WIRB-Copernicus Group Institutional Review Board who waived the approval due to the study only including interactions involving survey procedures, having adequate provisions to protect the privacy of subjects and maintain confidentiality of data, following review under the Common Rule and based on Code of Federal Regulations Title 45, Part 46, Subpart A, Sect.\u00a046.104d, Category 2 criteria. Informed consent was taken from each study participant before initiating the survey. The study was conducted in compliance with the Declaration of Helsinki and its amendments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Amy Perrin Ross has received consulting fees from Alexion, BMS, EMD Serono, Horizon, Novartis, Roche, Sanofi, and TG Therapeutics. Jacqueline Nicholas has received research grants from Biogen, Genentech, Novartis, PCORI, and the University of Buffalo; has received consulting fees from EMD Serono, Genentech, Greenwich Biosciences, Novartis, Sanofi, and\u00a0TG Therapeutics; and has received\u00a0speaking honoraria from BMS, EMD Serono, Horizon, and\u00a0TG Therapeutics. Ming-Hui Tai and Stephen Yeung are employees of Novartis Pharmaceuticals Corporation. Nazneen Fatima Shaikh, Helen Chen, Mariana Fernandes, Aaron Cortright, and Kevin Hawkins are employees of Real World Solutions, IQVIA.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"28"}}